Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

Saint-Herblain (France), August 14, 2023– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials